Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As Adjunctive Treatment In Adult Patients With Partial Onset Seizures
Linkedin

Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As Adjunctive Treatment In Adult Patients With Partial Onset Seizures

Alexandria : VA : USA | Nov 16, 2012 at 5:56 AM PST
Source: The Motley Fool
XX XX
Views: Pending
 
today announced top-line results of a double-blind, placebo-controlled, Phase 3 study evaluating both the 165 mg dose and the 330 mg dose of pregabalin controlled-release (CR) formulation in adult patients with partial onset seizures with epilepsy. FULL ARTICLE AT The Motley Fool
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

News Stories

 
  • Once-daily Lyrica trial fails to meet goal

      Fox News
    Reuters Pfizer Inc. said Friday a late-stage trial of a once-a-day formulation of its drug pregabalin did not significantly reduce the frequency of some types of seizures in patients with epilepsy. Pfizer's biggest product, sold under the brand name...
  • Pfizer: Once-a-day Lyrica failed in epilepsy trial

      Seattle Post Intelligencer
    Pfizer says that a long-lasting version of its anti-seizure drug Lyrica failed to significantly decrease epilepsy symptoms when compared with placebo. The company said Friday that a study of two doses of once-a-day pregabalin CR showed the pills were...

More From Allvoices



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.